Caribou Biosciences, Inc.
CRBU
$1.44
-$0.10-6.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.02% | 12.96% | 11.66% | -19.00% | -72.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.02% | 12.96% | 11.66% | -19.00% | -72.45% |
| Cost of Revenue | -30.89% | -28.34% | -15.92% | -11.36% | -3.89% |
| Gross Profit | 34.14% | 31.70% | 18.21% | 10.63% | -19.76% |
| SG&A Expenses | -16.63% | -12.77% | -18.39% | -12.84% | -11.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.38% | -24.61% | -16.57% | -11.74% | -5.79% |
| Operating Income | 29.58% | 26.89% | 18.26% | 11.24% | -9.80% |
| Income Before Tax | 36.72% | 9.54% | 0.29% | -6.23% | -33.29% |
| Income Tax Expenses | -6,011.11% | -6,011.11% | -6,011.11% | -104.66% | -104.66% |
| Earnings from Continuing Operations | 37.05% | 9.90% | 0.66% | -6.08% | -33.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.05% | 9.90% | 0.66% | -6.08% | -33.07% |
| EBIT | 29.58% | 26.89% | 18.26% | 11.24% | -9.80% |
| EBITDA | 29.10% | 26.84% | 18.53% | 11.89% | -9.49% |
| EPS Basic | 39.65% | 12.51% | 3.83% | -2.72% | -28.60% |
| Normalized Basic EPS | 34.54% | 20.21% | 11.38% | 5.04% | -19.39% |
| EPS Diluted | 39.65% | 12.51% | 3.83% | -2.72% | -28.60% |
| Normalized Diluted EPS | 34.54% | 20.21% | 11.38% | 5.04% | -19.39% |
| Average Basic Shares Outstanding | 4.72% | 3.31% | 3.40% | 3.24% | 4.40% |
| Average Diluted Shares Outstanding | 4.72% | 3.31% | 3.40% | 3.24% | 4.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |